← Browse by Condition
Medical Condition
esophagogastric junction adenocarcinoma
Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2, Phase 1
ClinicalMetric tracks all active clinical trials for esophagogastric junction adenocarcinoma sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.
- Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
- Phase 1–4 studies from early safety trials to post-marketing surveillance
- NIH, pharmaceutical sponsor, and academic medical center studies worldwide
- AI-powered plain-language summary available for every trial listing
Trial Phases
Phase 1 1
Phase 2 2
Top Sponsors
1 trial
1 trial
1 trial
NCT06461910 Phase 2
Recruiting
Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma
Enrollment
30 pts
Location
China
Sponsor
Zekuan Xu
NCT07059299 Phase 1
Recruiting
A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma
Enrollment
18 pts
Location
Germany
Sponsor
Institut für Klinische Krebsfo...
NCT06482788 Phase 2
Recruiting
Perioperative Treatment of Resectable Adenocarcinoma of Esophagogastric Junction by Immunotherapy (Adebrelimab) Combined With Chemotherapy (XELOX): a Prospective, Single-center, Feasibility Study
Enrollment
26 pts
Location
China
Sponsor
Ruijin Hospital
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology